Bruno Daniele Leoni

Dr. Bruno Daniele Leoni

Abbott Laboratories (Italy), Rome, Lazio, Italy
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2012 in Toxicology in Vitro
Verified
Journal Article
Closed access
MNManuela Natoli
Manuela Natoli
BLBruno Daniele Leoni
Bruno Daniele Leoni
Igea D'AgnanoIgea D'Agnano
Igea D'Agnano
FZFlavia Zucco
Flavia Zucco
AFArmando Felsani
Armando Felsani

13 October 2010 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
MNManuela Natoli
Manuela Natoli
BLBruno Daniele Leoni
Bruno Daniele Leoni
Igea D'AgnanoIgea D'Agnano
Igea D'Agnano
MDMara D'ONofrio
Mara D'ONofrio
RBRossella Brandi
Rossella Brandi
AFArmando Felsani
Armando Felsani

23 June 2021 in Clinical Chemistry and Laboratory Medicine (CCLM)
Verified
Journal Article
Closed access
SMSilvia Meschi
Silvia Meschi
GMGiulia Matusali
Giulia Matusali
FCFrancesca Colavita
Francesca Colavita
DLDaniele Lapa
Daniele Lapa
LBLicia Bordi
Licia Bordi
OTon behalf of INMI Covid-19 laboratory and investigation team
on behalf of INMI Covid-19 laboratory and investigation team
Objectives: Simple and standardized methods to establish correlates to vaccine-elicited SARS-CoV-2 protection are needed. Methods: An observational study on antibody response to a mRNA vaccine (Comirnaty) was performed on health care workers (V, n=120). Recovered COVID-19 patients (N, n=94) were used for comparison. Antibody response was evaluated by a quantitative anti-receptor binding domain IgG (anti-RBD) commercial assay and by virus microneutralization test (MNT), in order to establish a threshold of anti-RBD binding antibody units (BAU) able to predict a robust (≥1:80) MNT titer. Results: Significant correlation between BAU and MNT titers was found in both V and N, being stronger in V (rs=0.91 and 0.57 respectively, p<0.001); a higher incremental trend starting from MNT titer 1:80 was observed in the V group. The 99% probability of high MNT titer (≥1:80) was reached at 1,814 and 3,564 BAU/mL, and the area under the receiver operating characteristic (ROC) curve was 0.99 (CI: 0.99–1.00) and 0.78 (CI: 0.67–0.86) in V and N, respectively. Conclusions: A threshold of 2,000 BAU/mL is highly predictive of strong MNT response in vaccinated individuals and may represent a good surrogate marker of protective response. It remains to be established whether the present results can be extended to BAU titers obtained with other assays.

7 March 2024 in Viruses
Verified
Journal Article
Open access
PDF file
SMSilvia Meschi
Silvia Meschi
KMKlizia Mizzoni
Klizia Mizzoni
BLBruno Daniele Leoni
Bruno Daniele Leoni
CGClaudio Galli
Claudio Galli
Anna Rosa GarbugliaAnna Rosa Garbuglia
Anna Rosa Garbuglia
TGthe HBSAGN Study Group
the HBSAGN Study Group
We investigated the frequency and serological correlates of occult hepatitis B virus infection (OBI) and the potential impact of a highly sensitive assay for HBsAg in subjects infected by human immunodeficiency virus (HIV) or hepatitis C virus (HCV), who are also at risk for hepatitis B virus (HBV) infection, often in an occult form. Samples from 499 patients with HIV, all HBsAg negative and anti-HBc positive, and 137 patients with HCV were tested for HBV-DNA, anti-HBc, anti-HBs, and HBsAg by a conventional and highly sensitive assay. HBV biomarkers were detected in 71.5% of HCV-RNA-positive, with a higher prevalence of cases positive only for anti-HBc in patients with HCV than in those with HIV. HBV-DNA was detectable in 0.6% of HIV-positive and 7.3% of HCV-RNA-positive patients. Among patients with HCV, four were positive for HBsAg and negative for HBV-DNA, bringing the rate of HBV-active infection in this group to 10.2%. Active HBV infection was not related to gender or specific patterns of HBV biomarkers but was higher in HCV patients coinfected by HIV compared to those infected only by HCV. Monitoring patients at high risk for HBV infection and reactivation may require testing for both HBV-DNA and HBsAg.

1 March 2012 in Differentiation
Verified
Journal Article
Closed access
BLBruno Daniele Leoni
Bruno Daniele Leoni
MNManuela Natoli
Manuela Natoli
MNMarta Nardella
Marta Nardella
BBBarbara Bucci
Barbara Bucci
FZFlavia Zucco
Flavia Zucco
AFArmando Felsani
Armando Felsani

8 June 2021 in Clinica Chimica Acta
Verified
Journal Article
Closed access
Marilena MinieriMarilena Minieri
Marilena Minieri
BLBruno Daniele Leoni
Bruno Daniele Leoni
LBLorenza Bellincampi
Lorenza Bellincampi
DBDaniela Bajo
Daniela Bajo
AAAlessia Agnoli
Alessia Agnoli
SBSergio Bernardini
Sergio Bernardini